Viz.ai announced a vital healthtech partnership today. They officially teamed up with Alnylam Pharmaceuticals. Together, they will launch an innovative AI care pathway. This system accelerates early cardiac amyloidosis detection effectively.
Specifically, this progressive condition causes severe heart failure. Misfolded proteins continuously deposit into the heart muscle. Consequently, patients suffer poor outcomes without quick treatment. Currently, doctors leave many affected patients completely undiagnosed. Furthermore, diagnosed patients face massive treatment delays regularly.
“Cardiac amyloidosis is a condition where delayed diagnosis has real consequences in heart failure – earlier identification can fundamentally alter a patient’s trajectory,” said Tim Showalter, MD, Chief Medical Officer of Viz.ai. “This partnership is about making early detection actionable. By combining advanced imaging and generative AI with a care coordination platform, we will help clinicians find the right patients earlier and move them swiftly toward appropriate care before the window for meaningful intervention narrows.”
Transforming Cardiac Care Procedures
Therefore, Viz.ai is developing this specialized AI care pathway. The tool actively guides doctors through guideline-based steps. It utilizes an FDA-cleared AI echocardiography algorithm effortlessly. Additionally, the smart software quickly analyzes standard echocardiograms. Then, it immediately identifies patients showing suggestive symptoms.
“ATTR-CM is recognized late far too often, after patients have spent years searching for answers while the disease silently progresses,” said Sameer Bansilal, M.D., M.S., Cardiologist and Vice President, Global TTR Medical Lead, Alnylam Pharmaceuticals. “By partnering with Viz.ai, we are bringing AI into everyday clinical decision-making, helping clinicians detect warning signs earlier, initiate appropriate diagnostic testing sooner, and ultimately deliver more timely, coordinated care for patients.”
Ultimately, this important partnership thoroughly transforms standard care procedures. Alnylam intentionally aims to shift medical diagnoses much earlier. Soon, a comprehensive multi-site pilot study will launch officially. This initial study will effectively evaluate clinical workflow integration. Finally, this robust AI care pathway expands the Viz platform. Presently, over two thousand hospitals actively use this software.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
